

UBE2D3 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP16801b

Specification

UBE2D3 Antibody (C-term) - Product Information

Application	WB,E
Primary Accession	P61077
Other Accession	P61078 , P61079 , O4R5N4 , O3ZCF7 , O06AA9 , NP_003331.1 , NP_871615.1
Reactivity	Human
Predicted	Pig, Bovine, Monkey, Mouse, Rat
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	16687
Antigen Region	109-136

UBE2D3 Antibody (C-term) - Additional Information

Gene ID 7323

Other Names

Ubiquitin-conjugating enzyme E2 D3, Ubiquitin carrier protein D3, Ubiquitin-conjugating enzyme E2(17)KB 3, Ubiquitin-conjugating enzyme E2-17 kDa 3, Ubiquitin-protein ligase D3, UBE2D3, UBC5C, UBCH5C

Target/Specificity

This UBE2D3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 109-136 amino acids from the C-terminal region of human UBE2D3.

Dilution

WB~~1:1000

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

UBE2D3 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

UBE2D3 Antibody (C-term) - Protein Information

Name UBE2D3

Synonyms UBC5C, UBCH5C

Function Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins (PubMed:[15247280](#), PubMed:[15496420](#), PubMed:[18284575](#), PubMed:[20061386](#), PubMed:[21532592](#), PubMed:[28322253](#)). In vitro catalyzes 'Lys-11'-, as well as 'Lys-48'- linked polyubiquitination (PubMed:[15247280](#), PubMed:[15496420](#), PubMed:[18284575](#), PubMed:[20061386](#), PubMed:[21532592](#)). Cooperates with the E2 CDC34 and the SCF(FBXW11) E3 ligase complex for the polyubiquitination of NFKBIA leading to its subsequent proteasomal degradation (PubMed:[20347421](#)). Acts as an initiator E2, priming the phosphorylated NFKBIA target at positions 'Lys-21' and/or 'Lys-22' with a monoubiquitin (PubMed:[10329681](#)). Ubiquitin chain elongation is then performed by CDC34, building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin (PubMed:[10329681](#)). Acts also as an initiator E2, in conjunction with RNF8, for the priming of PCNA (PubMed:[18948756](#)). Monoubiquitination of PCNA, and its subsequent polyubiquitination, are essential events in the operation of the DNA damage tolerance (DDT) pathway that is activated after DNA damage caused by UV or chemical agents during S-phase (PubMed:[18948756](#)). Associates with the BRCA1/BARD1 E3 ligase complex to perform ubiquitination at DNA damage sites following ionizing radiation leading to DNA repair (PubMed:[16628214](#)). Targets DAPK3 for ubiquitination which influences promyelocytic leukemia protein nuclear body (PML-NB) formation in the nucleus (PubMed:[18515077](#)). In conjunction with the MDM2 and TOPORS E3 ligases, functions ubiquitination of p53/TP53 (PubMed:[12646252](#), PubMed:[15280377](#)). In conjunction with the CBL E3 ligase, targets EGFR for polyubiquitination at the plasma membrane as well as during its internalization and transport on endosomes (PubMed:[18508924](#)). In conjunction with the STUB1 E3 quality control E3 ligase, ubiquitinates unfolded proteins to catalyze their immediate destruction (PubMed:[11743028](#)). Together with RNF135, catalyzes the viral RNA-dependent 'Lys-63'-linked polyubiquitination of RIGI to activate the downstream signaling pathway that leads to interferon beta production (PubMed:[28469175](#)). Together with ZNF598, catalyzes ubiquitination of 40S ribosomal proteins in response to ribosome collisions (PubMed:[28685749](#)). In cooperation with the GATOR2 complex, catalyzes 'Lys-6'-linked ubiquitination of NPRL2 (PubMed:[36528027](#)).

Cellular Location

Cell membrane; Peripheral membrane protein. Endosome membrane; Peripheral membrane protein


UBE2D3 Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

UBE2D3 Antibody (C-term) - Images





UBE2D3 Antibody (C-term) (Cat. #AP16801b) western blot analysis in HeLa cell line lysates (35ug/lane). This demonstrates the UBE2D3 antibody detected the UBE2D3 protein (arrow).



Western blot analysis of UBE2D3 (arrow) using rabbit polyclonal UBE2D3 Antibody (C-term) (Cat. #AP16801b). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected (Lane 2) with the UBE2D3 gene.

UBE2D3 Antibody (C-term) - Background

The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. This enzyme functions in the ubiquitination of the tumor-suppressor protein p53, which is induced by an E3 ubiquitin-protein ligase. Multiple spliced transcript variants have been found for this gene, but the full-length nature of some variants has not been determined.

UBE2D3 Antibody (C-term) - References

- Kalsi, G., et al. Hum. Mol. Genet. 19(12):2497-2506(2010)
- Wu, K., et al. Mol. Cell 37(6):784-796(2010)
- Vina-Vilaseca, A., et al. J. Biol. Chem. 285(10):7645-7656(2010)
- Markson, G., et al. Genome Res. 19(10):1905-1911(2009)
- van Wijk, S.J., et al. Mol. Syst. Biol. 5, 295 (2009) :